Navigation Links
Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
Date:7/25/2008

- Management to discuss second quarter financial results -

LAVAL, QC, July 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, August 8 at 8:30 a.m. (ET) to discuss its second quarter 2008 financial results. Labopharm will report its second quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-646-3095 or 1-800-814-4859. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 15, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21278611 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
2. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
3. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
4. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
5. Labopharm Reports Results for First Quarter Fiscal 2008
6. Labopharm announces details for first quarter results conference call and annual meeting
7. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
8. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
9. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
10. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
11. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... ... is launching a new client service center in La Vergne, Tennessee, near Nashville. ... provide the full range of Empyrean client services. , “Our Nashville-area center allows ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer from ... the United States and account for one death every four minutes. Many people ... disabled. HCR ManorCare is launching a video series called “Your Brain,” in conjunction with ...
(Date:5/3/2016)... Indianapolis, IN (PRWEB) , ... May 03, 2016 ... ... employee benefits advisory organization, announces Benefits Alliance Insurance Services as the latest addition ... powerhouse Southern California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul ...
(Date:5/3/2016)... ... May 03, 2016 , ... Octo ... solutions and digital consulting services to the federal government, has been awarded a ... / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive ...
(Date:5/3/2016)... ... May 03, 2016 , ... AvePoint, ... release of DocAve 6 Service Pack (SP) 7, the enterprise-class infrastructure ... 2016 and take advantage of the platform’s latest features – whether in an ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... May 2, 2016 Kalorama Information noted the ... Records) market in a recent white paper.  The healthcare ... physician usage, a growing market are among the top ... Kalorama,s report EMR 2016: The Market for ... seventh complete study of the EMR industry, and the ...
(Date:5/2/2016)... , May 2, 2016  Deerfield announced ... financing of Graybug Vision, Inc. Graybug Vision is ... therapies that may transform care for ocular diseases ... Graybug Vision,s technology was first developed at Johns ... a startup venture. Graybug Vision ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
Breaking Medicine Technology: